Inclusion Criteria:  Male or female adults aged between 18 and 45 years Written and signed informed consent Examined by a study physician before treatment Provided two stool samples at baseline Trichuris trichiura and hookworm EPG > 48 and at least two Kato-Katz thick smears slides with more than one Trichuris trichiura and hookworm eggs  Exclusion Criteria:  Pregnant or lactating and/or planning to become pregnant within three months after drug treatment Type 1 and/or 2 diabetes Psychiatric disorders History of ophthalmological conditions Presence or history of major systemic or chronic illnesses, as assessed by a medical doctor, during initial clinical assessment Suffers from severe anaemia (Hb < 80 g/l) Received anthelminthic treatment within past four weeks Attending other clinical trials during the study Received strong CYP3A4 inducers or inhibitors as well as concomitant treatments that are relevant substrate for CYP3A4 such as clarithromycin, erythromycin and rifampicin Received strong P-gp inhibitors as well as concomitant treatments that are relevant substrates for P-gp such as clotrimazole and ritonavir